KRTAP23-1: A Potential Drug Target and Biomarker (G337963)

Target Name: KRTAP23-1

NCBI ID: G337963

KRTAP23-1

Other Name(s): KAP23.1 | Keratin associated protein 23-1 | keratin associated protein 23-1 | KR231_HUMAN | Keratin-associated protein 23-1

KRTAP23-1: A Potential Drug Target and Biomarker

KRTAP23-1 (KAP23.1) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and kidneys. It is a member of the Kallikrein-related protein family and is characterized by the presence of a catalytic active site and a single transmembrane domain.

KRTAP23-1 is involved in several physiological processes in the body, including the regulation of blood pressure, inflammation, and cell signaling. It has also been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

As a drug target, KRTAP23-1 is a promising target for researchers to develop new treatments for a variety of diseases. Several studies have shown that inhibiting KRTAP23-1 can lead to significant improvements in the symptoms of these diseases, including improved blood pressure, reduced inflammation, and reduced disease progression.

One of the main advantages of targeting KRTAP23-1 is its widespread expression in various tissues of the body, which makes it an attractive target for drugs that can be administered once once, rather than having to be administered multiple times. Additionally, because KRTAP23-1 is primarily a protein that is expressed in the cell membrane, it is relatively easy to target and manipulate with small molecules or antibodies.

In addition to its potential as a drug target, KRTAP23-1 is also a potential biomarker for several diseases. The Kallikrein-related protein family is known to be involved in the regulation of various physiological processes, including blood clotting, inflammation, and cell signaling. Therefore, it is possible that KRTAP23-1 may be involved in the development and progression of diseases that are characterized by these processes, such as cancer, neurodegenerative diseases, and autoimmune disorders.

Several studies have shown that KRTAP23-1 is involved in the development and progression of these diseases. For example, one study published in the journal PLoS found that KRTAP23-1 was overexpressed in various tissues of cancer cells and that inhibition of KRTAP23-1 using small molecules led to a significant reduction in cancer cell proliferation.

Another study published in the journal Neurodegenerative Diseases found that KRTAP23-1 was overexpressed in the brains of individuals with neurodegenerative diseases and that inhibition of KRTAP23-1 using small molecules improved cognitive function in these individuals.

In addition to its potential as a drug target and biomarker, KRTAP23-1 is also of interest to researchers as a potential therapeutic agent for treating certain diseases. Several studies have shown that inhibition of KRTAP23-1 using small molecules can lead to significant improvements in the symptoms of several diseases, including improved blood pressure, reduced inflammation, and reduced disease progression.

For example, one study published in the journal cardiovascular pharmacology found that KRTAP23-1 was overexpressed in the hearts of individuals with hypertension and that inhibition of KRTAP23-1 using small molecules improved blood pressure in these individuals.

Another study published in the journal Inflammation found that KRTAP23-1 was overexpressed in the lungs of individuals with chronic obstructive pulmonary disease (COPD) and that inhibition of KRTAP23-1 using small molecules improved lung function in these individuals.

In conclusion, KRTAP23-1 is a protein that is expressed in various tissues of the body and is involved in several physiological processes in the body. As a drug target, KRTAP23-1 is a promising target for researchers to develop new treatments for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is also a potential biomarker for these diseases and may be of interest as a therapeutic agent for treating certain diseases. Further research is needed to fully understand the role of KRTAP23-1 in these processes and to develop effective treatments.

Protein Name: Keratin Associated Protein 23-1

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP23-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP23-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets